Your donation will make a difference:
Cystic Fibrosis Trust
Forum

Trials Tracker

Welcome to the Trials Tracker, bringing together all the cystic fibrosis (CF) trials currently recruiting in the UK so that you can find clinical trials you can take part in both in your region and further afield. The Trials Tracker is a new resource that we’ll be developing over time based on your feedback. If you’ve used the Trials Tracker and want to share your opinion, please complete our online poll or get in touch at clinicaltrials@cysticfibrosis.org.uk.

Please Log in

Log in

Not a registered user? Register with us

This trial has been added to your watchlist.

Do you want to receive email notifications when the trial status changes?

No Yes

Unfollowing a trial will remove it from the watchlist and stop status change email notifications

Are you sure you want to unfollow this trial?

Yes, remove from watchlist

Clinical trials

21-25 of 54 results for all trials

Sort by:

Filter by

Trial status

Inclusion age

FEV1

Trial type

Location

Mutation

Therapeutic category

Gut - CF

Cystic fibrosis affects the digestive system and leads to a number of unpleasant symptoms. Those relating to the bowels are often overlooked and can be hard to treat. We are hoping to evaluate a new questionnaire –the CF bowel score (CF-BS)–specifically designed to look at CF bowel disease. We hope it will improve identification and allow us to measure response to treatment. The patient will complete the CF-BS at their routine clinic appointment along with providing relevant clinical information. One group of patients will be sent home with the CF-BS to complete at home and return to us within a week. A final group of patients will be asked to complete the form before and after certain treatments so we can assess how bowel symptoms change over a course of treatment. Once we are happy that the CF-BS questionnaire captures symptoms that affect CF patients it will be distributed to the rest of the patients at the Manchester Adult CF Centre. This will allow us to identify the number of patients with bowel symptoms and allow us to better treat them

Read more
  • Trial Reference Number

    106002

  • Age

    18+

  • Length of participation

    1 week

  • Trial status

    Closed - follow up complete

  • Therapeutic category

    Other

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy (VX17-445-105)

This study will evaluate the long-term safety and tolerability of VX-445 in triple combination withT ezacaftor (TEZ) and Ivacaftor (IVA) in subjects with cystic fibrosis who are homozygous or heterozygous for the F508del mutation..

Phase III
  • Trial Reference Number

    109563

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

GLPG2737-CL-105 Assessment of multiple oral doses of GLPG2451/GLPG2222

This is a Phase Ib, multi-center, open-label, nonrandomized multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of a combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in adult subjects with Cystic Fibrosis.

Read more Phase I
  • Trial Reference Number

    104923

  • Age

    18+

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy (VX17-659-105)

This study will evaluate the long-term safety and tolerability of VX-659 in triple combination with Tezacaftor and Ivacaftor in subjects with cystic fibrosis (CF), including but not limited to those who are heterozygous for the F508del mutation

Phase III
  • Trial Reference Number

    108792

  • Trial status

    Closed to recruitment - in follow up

  • Therapeutic category

    Restore CFTR Function

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

This is a Phase 2 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of cystic fibrosis in patients 12 years of age or older. Approximately 415 subjects will be enrolled in this study

Read more Phase II
  • Trial Reference Number

    106210

  • Trial status

    Open to recruitment

  • Therapeutic category

    Anti-Inflammatory

21-25 of 54 results for all trials